StepStone Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

StepStone Group’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,573,357	Closed	-$2.5M	–	23
2024 Q1	$2.5M	Hold	1,573,357	–	–	0.53%	13
2023 Q4	$1.35M	Hold	1,573,357	–	–	0.24%	14
2023 Q3	$1.68M	Hold	1,573,357	–	–	0.38%	13
2023 Q2	$4.07M	Hold	1,573,357	–	–	0.75%	11
2023 Q1	$7.9M	Hold	1,573,357	–	–	1.47%	10
2022 Q4	$7.9M	Hold	1,573,357	–	–	1.03%	13
2022 Q3	$20.6M	Hold	1,573,357	–	–	2.93%	8
2022 Q2	$20.2M	Hold	1,573,357	–	–	2.16%	9
2022 Q1	$24M	Hold	1,573,357	–	–	1.79%	11
2021 Q4	$27.9M	Hold	1,573,357	–	–	1.59%	10
2021 Q3	$33.1M	Buy	+1,573,357	New	+$34.6M	2.14%	8

StepStone Group's NGM Position: Q2 2024 in Review

StepStone Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 1,573,357 shares — an estimated $2.5M sold.

StepStone Group first reported a position in NGM in Q3 2021 and held it in 11 quarters. The position peaked at $33.1M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

StepStone Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
StepStone Group sold 1,573,357 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $2.5M.
StepStone Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 11 quarters.
StepStone Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $33.1M in Q3 2021.
0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on StepStone Group's 13F filing for Q2 2024, filed 14 Aug 2024.